• Release your full potential

    Be active. Be free. Experience superior treatment with PAD TM Technology based drugs

ABOUT US

MC2 Therapeutics is a commercial stage pharmaceutical company committed to optimize the treatment experience and address unmet needs for patients with autoimmune and chronic inflammatory conditions through innovative best in class or first in class topical therapies tailored for fast and safe relief of symptoms in formulations that patients prefer to use in daily routines. Read more about MC2 Therapeutics.

Platform

Our PAD™ Technology offers several unique advantages in the development of potent innovative new topical therapies for auto-immune and inflammatory conditions, including stability, tolerability, delivery to target tissue and convenience of use in daily routines. Read more about our platform.

Pipeline

MC2 therapeutics is uncovering new topical therapies within the field of autoimmune and inflammatory conditions. We are proud to take leadership in setting a new standard powered by our PAD™ Technology, our research into the root causes of poorly understood autoimmune and chronic inflammatory conditions and our ability to effectively execute on development of best in class or first in class innovative topical therapies. Read more about our pipeline.

LATEST NEWS

mc2_news-image-icon-04

MC2 Therapeutics’ clinical research to be presented in four poster presentations at the European Academy of Dermatology and Venereology conference - EADV 2021

  • Poster # P1447: A pooled analysis of randomized, controlled, phase 3 trials investigating the efficacy ...

    READ FULL ARTICLE

mc2_news-image-icon-05

Almirall and MC2 Therapeutics enter a License, Collaboration and Commercialization Agreement for European Rights to WYNZORA® Cream for treatment of Plaque Psoriasis

In this collaboration Almirall will commercialize Wynzora® Cream for treatment of plaque psoriasis in Europe ...

READ FULL ARTICLE

 

mc2_news-image-icon-04

MC2 Therapeutics Announces Collaboration Agreement with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA® Cream, in the US

  • Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA® Cream to patients with plaque ...

    READ FULL ARTICLE

MC2 Therapeutics Announces U.S. Food and Drug Administration Approval of Wynzora® Cream (calcipotriene 0.005% and betamethasone dipropionate 0.064%) for Adults with Plaque Psoriasis

Copenhagen, July 22nd, 2020 – MC2 Therapeutics, a commercial stage pharmaceutical company developing a new ...

READ FULL ARTICLE

© mc2 therapeutics 2020